Biden's Successor: The Radical Threat to YOUR Savings!

Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.

>> Get Your FREE Wealth Protection Guide <<

Jonathan P. DiVincenzo net worth and biography

Jonathan DiVincenzo Biography and Net Worth

EVP and President, Central Laboratories and International of Laboratory Co. of America

Jon DiVincenzo has served as Executive Vice President and President, Central Laboratories and International at Labcorp since 2023.

Jon has been with Labcorp since 2017, most recently serving as head of Clinical Trials Testing Solutions (CTTS), with oversight of Central Laboratory Services (CLS), BioAnalytical and CMC laboratory services.

Under his leadership, Labcorp has made significant advancements in its global footprint to support growth and innovation. The company opened new anatomic pathology facilities in the United States and abroad, and completed the expansion of anatomic pathology, genomics and microbiology labs in Singapore, Shanghai and Japan. In addition, Jon led Labcorp’s efforts to automate its kit assembly line in Mechelen, Belgium and the construction of a new kit production facility in Suzhou, China.

Before joining Labcorp, he served as President of the Environmental Health division of PerkinElmer. He has held numerous leadership roles throughout his career including President and Chief Executive Officer at Enzymatics and President of the Bioscience Division of EMD Millipore, a subsidiary of Merk KGaA.

Jon holds a bachelor’s degree in mechanical engineering from Northeastern University.

What is Jonathan P. DiVincenzo's net worth?: The estimated net worth of Jonathan P. DiVincenzo is at least $761,517.91 as of February 21st, 2024. Mr. DiVincenzo owns 3,401 shares of Laboratory Co. of America stock worth more than $761,518 as of September 7th. This net worth evaluation does not reflect any other investments that Mr. DiVincenzo may own. Learn More about Jonathan P. DiVincenzo's net worth.
How do I contact Jonathan P. DiVincenzo?: The corporate mailing address for Mr. DiVincenzo and other Laboratory Co. of America executives is 358 South Main Street, BURLINGTON NC, 27215. Laboratory Co. of America can also be reached via phone at (336) 229-1127 and via email at [email protected]. Learn More on Jonathan P. DiVincenzo's contact information.
Has Jonathan P. DiVincenzo been buying or selling shares of Laboratory Co. of America?: Jonathan P. DiVincenzo has not been actively trading shares of Laboratory Co. of America in the last ninety days. Most recently, Jonathan P. Divincenzo sold 500 shares of the business's stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $215.49, for a transaction totalling $107,745.00. Following the completion of the sale, the executive vice president now directly owns 3,401 shares of the company's stock, valued at $732,881.49. Learn More on Jonathan P. DiVincenzo's trading history.
Who are Laboratory Co. of America's active insiders?: Laboratory Co. of America's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Lance Berberian (EVP), Brian Caveney (EVP), Jonathan DiVincenzo (EVP and President, Central Laboratories and International), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Laboratory Co. of America's active insiders.
Are insiders buying or selling shares of Laboratory Co. of America?: During the last year, insiders at the medical research company sold shares 18 times. They sold a total of 90,307 shares worth more than $19,790,066.68. The most recent insider tranaction occured on August, 19th when EVP Der Vaart Sandra D Van sold 2,000 shares worth more than $454,100.00. Insiders at Laboratory Co. of America own 0.9% of the company. Learn More about insider trades at Laboratory Co. of America.
Information on this page was last updated on 8/19/2024.

Jonathan P. DiVincenzo Insider Trading History at Laboratory Co. of America

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/21/2024	Sell	500	$215.49	$107,745.00	3,401

Jonathan P. DiVincenzo Buying and Selling Activity at Laboratory Co. of America

Laboratory Co. of America Company Overview

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Today's Range

Now: $223.91

$223.81

$229.70

50 Day Range

MA: $218.74

$199.35

$236.00

2 Week Range

Now: $223.91

$191.97

$238.46

Volume

488,233 shs

Average Volume

688,116 shs

Market Capitalization

$18.88 billion

P/E Ratio

45.05

Dividend Yield

1.26%

Beta

1.06